Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-05-14

Development of genetically engineered highly competent insulin-secreting cell lines

Objetivo



The objectives of the project are to: 1. develop highly competent insulin-secreting cell lines by genetic engineering. Such cells should respond to glucose as promptly and consistently as normal pancreatic beta-cells and should have high insulin content. 2. develop and optimise methods for micro-encapsulation of the engineered cells for protecting against immune damage; characterise conditions for growth and survival of beta-cells in the microcapsules.3. characterise mechanisms of signalling that mediates secretion in the native and the engineered cells before and after micro-encapsulation 4. transplant diabetic animals with highly competent insulin-secreting cells encapsulated in immune barrier and study the effects of such procedures on diabetic status and on the transplanted cells.
A hallmark of the approach would be to manipulate GLP-l- and CAMPmediated signalling pathways to increase competence of beta-cells.
Background works from the coordinator's laboratory establish critical role of CAMP system and the incretin hormone GLP-l in regulating stimulus-secretion coupling in pancreatic beta cells. Several of the currently available beta cell lines do respond to physiological range of glucose concentration but not as promptly and as consistently as does the normal beta cells. In the proposed project we shall engineer cells to stably express proglucagon which would be processed to GLP-l within the beta-cells and the engineered cells would secrete insulin and GLP-l. The latter would make beta cells competent by an autocrine interaction as well as provide GLP-l for other physiological functions. Variations of the approach namely expression of a constitutively active mutant of stimulatory subunit of G protein and a constitutively active mutant of GLP-l receptor will be pursued in the project. The response and insulin content will be further improved by iterative engineering with transfection of insulin and glucokinase gene as need be . The cells will be made resistant to apoptosis by expression of bc12. The engineered cells will be micro-encapsulated using modifications of methods for immunoisolation. The effects of engineering and encapsulations will be characterised by studying effects on growth, survival, secretion and cellular mechanisms of signalling. Finally the cells will be transplanted to murine diabetic models to assess the effects on diabetic status and performance of the cells under in-vivo conditions.

Ámbito científico (EuroSciVoc)

CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véas: El vocabulario científico europeo..

Para utilizar esta función, debe iniciar sesión o registrarse

Programa(s)

Programas de financiación plurianuales que definen las prioridades de la UE en materia de investigación e innovación.

Tema(s)

Las convocatorias de propuestas se dividen en temas. Un tema define una materia o área específica para la que los solicitantes pueden presentar propuestas. La descripción de un tema comprende su alcance específico y la repercusión prevista del proyecto financiado.

Convocatoria de propuestas

Procedimiento para invitar a los solicitantes a presentar propuestas de proyectos con el objetivo de obtener financiación de la UE.

Datos no disponibles

Régimen de financiación

Régimen de financiación (o «Tipo de acción») dentro de un programa con características comunes. Especifica: el alcance de lo que se financia; el porcentaje de reembolso; los criterios específicos de evaluación para optar a la financiación; y el uso de formas simplificadas de costes como los importes a tanto alzado.

CSC - Cost-sharing contracts

Coordinador

KAROLINSKA INSTITUTE
Aportación de la UE
Sin datos
Dirección
Karolinska Hospital
171 76 STOCKHOLM
Suecia

Ver en el mapa

Coste total

Los costes totales en que ha incurrido esta organización para participar en el proyecto, incluidos los costes directos e indirectos. Este importe es un subconjunto del presupuesto total del proyecto.

Sin datos

Participantes (2)

Mi folleto 0 0